JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB275614

APC Anti-LDL Receptor antibody [301]

Be the first to review this product! Submit a review

|

(5 Publications)

Anti-LDL Receptor antibody [301] - APC conjugated (ab275614) is a rabbit recombinant monoclonal antibody detecting LDL Receptor in Flow Cytometry. Suitable for Human.

- Recombinant format for unrivalled batch-batch consistency

View Alternative Names

Low-density lipoprotein receptor, LDL receptor, LDLR

1 Images
Flow Cytometry - APC Anti-LDL Receptor antibody [301] (AB275614)
  • Flow Cyt

Supplier Data

Flow Cytometry - APC Anti-LDL Receptor antibody [301] (AB275614)

Flow cytometric analysis A431 (human epidermoid carcinoma cell line) cells labeling LDL Receptor with ab275614 at 5 μL per test (Black) compared to an isotype control (Grey).

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

301

Isotype

IgG

Conjugation

APC

Excitation/Emission

Ex: 650nm, Em: 660nm

Carrier free

No

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Recombinant Fragment Protein within Human Low-density lipoprotein receptor aa 1-800. The exact immunogen used to generate this antibody is proprietary information.

P01130

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p>Use 5 μl/test.</p>" } } }

Product details

What is this antibody validated in?
APC Anti-LDL Receptor antibody [301] (ab275614) is a rabbit recombinant monoclonal antibody and is validated for use in Flow Cytometry (Flow Cyt) in Human samples.

Related products
Antibody clone 301 is also available pre-conjugated to a variety of labels for your convenience – Anti-LDL Receptor APC [301] (ab275614).

Other related products
We have a range of other formats of antibody clone [301] also available for your convenience: APC - ab275614, Carrier free - ab276036

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.09% Sodium azide Constituents: 0.5% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Do Not Freeze|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The LDL Receptor also called LDLR is a protein that plays an important role in the uptake and clearance of low-density lipoproteins (LDL) from the bloodstream. LDLR binds LDL particles facilitating their internalization through receptor-mediated endocytosis. This receptor is expressed mainly in the liver adrenal glands and other tissues involved in cholesterol metabolism. It has an approximate molecular weight of 160 kDa. Researchers often study LDLR using techniques like Western blotting to understand its presence and function.
Biological function summary

The LDL receptor interacts with LDL particles to regulate cholesterol levels in the body. It is part of a cell surface complex that recognizes and binds to apolipoprotein B-100 or apolipoprotein E present on LDL. This interaction initiates internalization of LDL leading to its degradation in lysosomes where cholesterol can be released and used by the cell. Mutations in the gene encoding LDLR can lead to inefficient cholesterol uptake influencing various metabolic processes.

Pathways

LDL receptor activities are integral to lipid metabolism and cholesterol homeostasis. Two important biological pathways that involve LDLR include the cholesterol biosynthesis pathway and the lipoprotein clearance pathway. Within these pathways LDLR collaborates closely with proteins like PCSK9 which modulates its expression and degradation and HMG-CoA reductase an important enzyme in cholesterol synthesis to balance cholesterol levels in the body.

Defects in the LDL receptor are strongly associated with familial hypercholesterolemia and atherosclerosis. These conditions arise from impaired clearance of LDL leading to elevated cholesterol levels which pose risks for cardiovascular diseases. LDLR dysfunctions are linked with the Protein PCSK9 whose gain-of-function mutations can exacerbate hypercholesterolemia by promoting degradation of LDLR while statins aim to increase LDLR expression to lower LDL cholesterol levels.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Binds low density lipoprotein /LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Forms a ternary complex with PGRMC1 and TMEM97 receptors which increases LDLR-mediated LDL internalization (PubMed : 30443021).. (Microbial infection) Acts as a receptor for hepatitis C virus in hepatocytes, but not through a direct interaction with viral proteins.. (Microbial infection) Acts as a receptor for Vesicular stomatitis virus.. (Microbial infection) In case of HIV-1 infection, may function as a receptor for extracellular Tat in neurons, mediating its internalization in uninfected cells.. (Microbial infection) Acts as a receptor for Crimean-Congo hemorrhagic fever virus (CCHFV).. (Microbial infection) Acts as a receptor for many Alphavirus, including Getah virus (GETV), Ross river virus (RRV) and Semliki Forest virus.
See full target information Low-density lipoprotein receptor

Publications (5)

Recent publications for all applications. Explore the full list and refine your search

Molecular genetics & genomic medicine 12:e70030 PubMed39600113

2024

Pathogenicity of the LDLR c.97C>T (p.Gln33Ter) Mutation in Familial Hypercholesterolemia.

Applications

Unspecified application

Species

Unspecified reactive species

Kaihan Wang,Tingting Hu,Mengmeng Tai,Yan Shen,Shaoyi Lin,Yongjuan Guo,Xiaomin Chen

Scientific reports 14:15592 PubMed38971841

2024

Production and stability of cultured red blood cells depends on the concentration of cholesterol in culture medium.

Applications

Unspecified application

Species

Unspecified reactive species

M J A G Claessen,N Yagci,K Fu,E Brandsma,M J Kersten,M von Lindern,E van den Akker

Lipids in health and disease 23:85 PubMed38515137

2024

LDLR c.415G > A causes familial hypercholesterolemia by weakening LDLR binding to LDL.

Applications

Unspecified application

Species

Unspecified reactive species

Kaihan Wang,Tingting Hu,Mengmeng Tai,Yan Shen,Haocheng Chai,Shaoyi Lin,Xiaomin Chen

Lipids in health and disease 22:77 PubMed37340302

2023

In vitro assessment of the pathogenicity of the LDLR c.2160delC variant in familial hypercholesterolemia.

Applications

Unspecified application

Species

Unspecified reactive species

Shaoyi Lin,Tingting Hu,Kaihan Wang,Jiaqi Wang,Yunyun Zhu,Xiaomin Chen

Journal of cellular biochemistry 122:1791-1804 PubMed34397115

2021

Mesenchymal stem cell and endothelial progenitor cells coinjection improves LPS-induced lung injury via Tie2 activation and downregulation of the TLR4/MyD88 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Sadaf Hoseinnia,Maryam Ghane,Jamile Norouzi,Farzaneh Hosseini
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com